Dr. Rogers Discusses Early Intervention With Ibrutinib in CLL

Kerry Rogers, MD
Published: Sunday, Dec 10, 2017


Kerry Rogers, MD, Assistant Professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of early intervention with ibrutinib (Imbruvica) in patients with asymptomatic, high-risk chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.

Having CLL, whether or not is has been treated, puts people at risk for secondary cancers and a higher rate of infection. As targeted agents become developed, the question becomes whether early intervention with these agents, like ibrutinib, can help patients avoid infectious complications, Rogers explains.
 

Kerry Rogers, MD, Assistant Professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of early intervention with ibrutinib (Imbruvica) in patients with asymptomatic, high-risk chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.

Having CLL, whether or not is has been treated, puts people at risk for secondary cancers and a higher rate of infection. As targeted agents become developed, the question becomes whether early intervention with these agents, like ibrutinib, can help patients avoid infectious complications, Rogers explains.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x